Association of doxycycline use with the development of gastroenteritis, irritable bowel syndrome and inflammatory bowel disease in Australians deployed abroad

Internal Medicine Journal

Volumn 43, Issue 8, 2013, Pages 919-926

  Lee, T W ^a,b   Russell, L ^a   Deng, M ^a   Gibson, Peter R ^a  

^a MONASH UNIVERSITY   (Australia)

^b WOLLONGONG HOSPITAL   (Australia)

Author keywords

Doxycycline; Gastroenteritis; Inflammatory bowel disease; Irritable bowel syndrome

Indexed keywords

ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; DOXYCYCLINE; MEFLOQUINE; ANTIMALARIAL AGENT;

ACUTE GASTROENTERITIS; ADULT; ARTICLE; AUSTRALIAN; CONTROLLED STUDY; CROHN DISEASE; CROSS-SECTIONAL STUDY; CYPRUS; DEVELOPED COUNTRY; DEVELOPING COUNTRY; FEMALE; HUMAN; INDONESIA; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; RISK FACTOR; SINGAPORE; SOLOMON ISLANDS; TIMOR-LESTE; ULCERATIVE COLITIS; UNITED KINGDOM; UNITED STATES; AUSTRALIA; CHEMICALLY INDUCED; GASTROENTERITIS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MIDDLE AGED; TRAVEL; TRENDS; CHEMICALLY INDUCED DISORDER;

ADULT; ANTIMALARIALS; AUSTRALIA; CROSS-SECTIONAL STUDIES; DOXYCYCLINE; FEMALE; GASTROENTERITIS; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; TRAVEL;

DOXYCYCLINE; GASTROENTERITIS; INFLAMMATORY BOWEL DISEASE; IRRITABLE BOWEL SYNDROME;

EID: 84896560315     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12179     Document Type: Article

References (34)

1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004; 126: 1504-17.
2. Halfvarson J, Jess T, Magnuson A, Montgomery SM, Orholm M, Tysk C et al. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis 2006; 12: 925-33.
3. Jeffery IB, O’Toole PW, Ohman L, Claesson MJ, Deane J, Quigley EM et al. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006.
4. Chassard C, Dapoigny M, Scott KP, Crouzet L, Del’homme C, Marquet P et al. Functional dysbiosis within the gut microbiota of patients with constipatedirritable bowel syndrome. Aliment Pharmacol Ther 2012; 35: 828-38.
5. Kennedy K, Collignon P. Colonisation with Escherichia coli resistant to ‘critically important’ antibiotics: a high risk for international travellers. Eur J Clin Microbiol Infect Dis 2010; 29: 1501-6.
6. Al-Abri SS, Beeching NJ, Nye FJ. Traveller’s diarrhoea. Lancet Infect Dis 2005; 5: 349-60.
7. Tuteja AK, Talley NJ, Gelman SS, Alder SC, Thompson C, Tolman K et al. Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA. Dig Dis Sci 2008; 53: 271-6.
8. Okhuysen PC, Jiang ZD, Carlin L, Forbes C, DuPont HL. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99: 1774-8.
9. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006; 101: 1894-9.
10. Thabane M, Kottachchi DT, Marshall JK. Systematic review and meta-analysis: the incidence and prognosis of postinfectious irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 535-44.
11. Shah ED, Riddle MS, Chang C, Pimentel M. Estimating the contribution of acute gastroenteritis to the overall prevalence of irritable bowel syndrome. J Neurogastroenterol Motil 2012; 18: 200-4.
12. Porter CK, Tribble DR, Aliaga PA, Halvorson HA, Riddle MS. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology 2008; 135: 781-6.
13. Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 2006; 130: 1588-94.
14. Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009; 137: 495-501.
15. Villarreal AA, Aberger FJ, Benrud R, Gundrum JD. Use of broad-spectrum antibiotics and the development of irritable bowel syndrome. WMJ 2012; 111: 17-20.
16. Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn’s disease. Gut 2004; 53: 246-50.
17. Hildebrand H, Malmborg P, Askling J, Ekbom A, Montgomery SM. Early-life exposures associated with antibiotic use and risk of subsequent Crohn’s disease. Scand J Gastroenterol 2008; 43: 61-6.
18. Shaw SY, Blanchard JF, Bernstein CN. Association between the use of antibiotics and new diagnoses of Crohn’s disease and ulcerative colitis. Am J Gastroenterol 2011; 106: 2133-42.
19. Margolis DJ, Fanelli M, Hoffstad O, Lewis JD. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease. Am J Gastroenterol 2010; 105: 2610-16.
20. United Nations Statistics Division. Composition of macro geographical (continental) regions, geographical sub-regions, and selected economic and other groupings. 2010. [cited 2013. Feb 11]. Available from URL: http://unstats.un.org/unsd/methods/m49/m49regin.htm
21. Wilson J, Hair C, Knight R, Catto-Smith A, Bell S, Kamm M et al. High incidence of inflammatory bowel disease in Australia: a prospective populationbased Australian incidence study. Inflamm Bowel Dis 2010; 16: 1550-6.
22. Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA et al. High incidence of Crohn’s disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm Bowel Dis 2006; 12: 936-43.
23. Swaminathan A, Torresi J, Schlagenhauf P, Thursky K, Wilder-Smith A, Connor BA et al. A global study of pathogens and host risk factors associated with infectious gastrointestinal disease in returned international travellers. J Infect 2009; 59: 19-27.
24. Echeverria P, Sack RB, Blacklow NR, Bodhidatta P, Rowe B, McFarland A. Prophylactic doxycycline for travelers’ diarrhea in Thailand. Further supportive evidence of Aeromonas hydrophila as an enteric pathogen. Am J Epidemiol 1984; 120: 912-21.
25. Sack DA, Kaminsky DC, Sack RB, Itotia JN, Arthur RR, Kapikian AZ et al. Prophylactic doxycycline for travelers’ diarrhea. Results of a prospective double-blind study of Peace Corps volunteers in Kenya. N Engl J Med 1978; 298: 758-63.
26. Gwee KA. Post-infectious irritable bowel syndrome, an inflammation-immunological model with relevance for other IBS and functional dyspepsia. J Neurogastroenterol Motil 2010; 16: 30-4.
27. Quigley EM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases? Chin J Dig Dis 2005; 6: 122-1232.
28. Heimdahl A, Nord CE. Influence of doxycycline on the normal human flora and colonization of the oral cavity and colon. Scand J Infect Dis 1983; 15: 293-302.
29. Myrvold HE, Larsson L, Brandberg A. Systemic prophylaxis with doxycycline in intestinal surgery on patients with high incidence of abnormal fecal flora. Acta Chir Scand 1989; 155: 277-80.
30. Mättö J, Maukonen J, Alakomi HL, Suihko ML, Saarela M. Influence of oral doxycycline therapy on the diversity and antibiotic susceptibility of human intestinal bifidobacterial population. J Appl Microbiol 2008; 105: 279-89.
31. Walker C, Preshaw PM, Novak J, Hefti AF, Bradshaw M, Powala C. Long-term treatment with sub-antimicrobial dose doxycycline has no antibacterial effect on intestinal flora. J Clin Periodontol 2005; 32: 1163-9.
32. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig Liver Dis 2009; 41: 850-3.
33. Lee KJ, Tack J. Altered intestinal microbiota in irritable bowel syndrome. Neurogastroenterol Motil 2010; 22: 493-8.
34. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. J Am Med Assoc 2006; 296: 2234-44.